BioSpace14h
5 CAR T Cell Therapies With Autoimmune Readouts in 2025
Having established success in cancer, biopharma is now looking to leverage CAR T therapies against a new target, autoimmune ...
The end of cancer: how cell therapy breakthroughs have us on the edge of a cure
Two years after Neil Armstrong walked on the Moon, US president Richard Nixon declared a new frontier in American scientific ...
Morningstar6d
GC Cell Initiates First Patient Dosing in Phase 1 Clinical Trial for GCC2005, a Promising T‑Cell Lymphoma CD5 CAR-NK Therapy
announced today the initiation of its domestic Phase 1 clinical trial for GCC2005 (AB‑205), a novel CD5 CAR‑NK cell therapy. This "first patient dosing" marks a critical milestone in the ...
Fierce Biotech5d
'I don't feel we lost momentum': Takeda’s oncology execs sharpen focus after restructuring
Takeda’s revamped R&D strategy means the drugmaker’s oncology leaders are prioritizing work in tumors across thoracic, ...
Science Daily8d
New CAR-T cell therapy shows promise for hard-to-treat cancers
Researchers have successfully developed a supercharged iteration of CAR-T cell therapy that can enhance the effectiveness and longevity of the cells, particularly against cancer cells that are harder ...
American Association of Individual Investors2d
Why Artiva Biotherapeutics, Inc.’s (ARTV) Stock Is Up 15.10%
Artiva Biotherapeutics, Inc.’s ARTV share price has surged by 15.10%, which has investors questioning if this is right time to sell.
GC Cell Initiates First Patient Dosing in Phase 1 Clinical Trial for GCC2005, a Promising T‑Cell Lymphoma CD5 CAR-NK Therapy
GC Cell (KRX:144510), under the leadership of CEO Sungyong Won, announced today the initiation of its domestic Phase 1 clinical trial for GCC2005 (AB‑205), a novel CD5 CAR‑NK cell therapy. This "first ...
Medindia5d
GC Cell Initiates First Patient Dosing in Phase 1 Clinical Trial for GCC2005, a Promising T-Cell Lymphoma CD5 CAR-NK Therapy
announced today the initiation of its domestic Phase 1 clinical trial for GCC2005 (AB-205), a novel CD5 CAR-NK cell therapy. This "first patient dosing" marks a critical milestone in the company's ...